Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-03-2011 | Basic Science

Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes

Authors: Sul Gee Lee, Jung Lim Kim, Han Kee Lee, Gyu Won Ryu, Dae Young Hur, Il Han Yun, Jae Wook Yang, Hyun Woong Kim

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 3/2011

Abstract

Background

Angiogenic factors such as vascular endothelial growth factor (VEGF), erythropoietin, and angiopoietin play important roles in the pathophysiology of diabetic retinopathy. Increased amounts of reactive oxygen species (ROS) are also known to associated with diabetic retinopathy and VEGF expression. This study evaluated the effect of a simvastatin on ROS generation and the changes in various angiogenic factors in the retinas of diabetic rats.

Methods

The rats were divided into normal, diabetes mellitus (DM), and simvastatin-treated groups (each group, n = 10). Diabetes was induced by intraperitoneal injection of streptozotocin into 20 Sprague–Dawley rats. After diabetic induction, simvastatin (5mg/kg) was administered orally to ten rats. The expression levels of VEGF, erythropoietin, angiopoietin 1 and 2, and NADPH oxidase were examined in rat retinas by RT-PCR and Western blot. Superoxide formation was examined by dihydroethidium (DHE) staining.

Results

DHE analysis revealed increased superoxide formation in the retinas of the diabetic group, which was decreased in the group treated with simvastatin. Western blot analysis showed that NADPH oxidase levels were decreased in the diabetic group and remained normal in the simvastatin-treated group. Simvastatin treatment blocked hyperglycemia-induced increases in VEGF, angiopoietin 2 and erythropoietin levels, as demonstrated by RT-PCR and Western blot analysis.

Conclusions

Simvastatin treatment led to suppression of superoxide formation and decreased expression of VEGF, angiopoietin 2 and erythropoietin in diabetic rat retinas.

Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–526PubMed

Lee P, Wang CC, Adamis AP (1998) Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 43:245–269PubMedCrossRef

The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef

Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP (1998) Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 101:1219–1224PubMedCrossRef

Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113:1538–1544PubMed

Ushio-Fukai M, Nakamura Y (2008) Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett 26:37–52CrossRef

Bartoli M, Platt D, Lemtalsi T, Gu X, Brooks SE, Marrero MB, Caldwell RB (2003) VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J 17:1562–1564PubMed

El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB (2003) Experimental diabetes causes breakdown of the blood–retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 162:1995–2004PubMedCrossRef

Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM, Frank RN, Stevens MJ (2001) Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 44:1102–1110PubMedCrossRef

10.

Ellis EA, Grant MB, Murray FT, Wachowski MB, Guberski DL, Kubilis PS, Lutty GA (1998) Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 24:111–120PubMedCrossRef

11.

Ellis EA, Guberski DL, Somogyi-Mann M, Grant MB (2000) Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat. Free Radic Biol Med 28:91–101PubMedCrossRef

12.

Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain SN (2005) Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J 19:1728–1730PubMed

13.

Kuroki M, Voest EE, Amano S, Beerepoot LV, Takashima S, Tolentino M, Kim RY, Rohan RM, Colby KA, Yeo KT, Adamis AP (1996) Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98:1667–1675PubMedCrossRef

14.

Griendling KK, Sorescu D, Ushio-Fukai M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86:494–501PubMed

15.

Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, Caldwell RB (2005) Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167:599–607PubMedCrossRef

16.

Ribatti D, Vacca A, Roccaro AM, Crivellato E, Presta M (2003) Erythropoietin as an angiogenic factor. Eur J Clin Invest 33:891–896PubMedCrossRef

17.

Joussen AM, Poulaki V, Tsujikawa A, Qin W, Qaum T, Xu Q, Moromizato Y, Bursell SE, Wiegand SJ, Rudge J, Ioffe E, Yancopoulos GD, Adamis AP (2002) Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 160:1683–1693PubMedCrossRef

18.

Pizurki L, Zhou Z, Glynos K, Roussos C, Papapetropoulos A (2003) Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. Br J Pharmacol 139:329–336PubMedCrossRef

19.

Witzenbichler B, Maisonpierre PC, Jones P, Yancopoulos GD, Isner JM (1998) Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase Tie2. J Biol Chem 273:18514–18521PubMedCrossRef

20.

Laufs U, Werner N, Link A, Endres M, Wassmann S, Jurgens K, Miche E, Bohm M, Nickenig G (2004) Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 109:220–226PubMedCrossRef

21.

Wassmann S, Faul A, Hennen B, Scheller B, Bohm M, Nickenig G (2003) Rapid effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res 93:98–103CrossRef

22.

Yamagishi S, Nakamura K, Matsui T, Sato T, Takeuchi M (2006) Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med Hypotheses 66:1019–1021PubMedCrossRef

23.

Al-Shabrawey M, Bartoli M, El-Remessy AB, Ma G, Matragoon S, Lemtalsi T, Caldwell RW, Caldwell RB (2008) Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci 49:3231–3238PubMedCrossRef

24.

Kowluru RA (2003) Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes 52:818–823PubMedCrossRef

25.

Anderson RE, Rapp LM, Wiegand RD (1984) Lipid peroxidation and retinal degeneration. Curr Eye Res 3:223–227PubMedCrossRef

26.

Caldwell RB, Bartoli M, Behzadian MA, El-Remessy AE, Al-Shabrawey M, Platt DH, Liou GI, Caldwell RW (2005) Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 6:511–524PubMedCrossRef

27.

Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 97:12222–12226PubMedCrossRef

28.

Maeda T, Kawane T, Horiuchi N (2003) Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology 144:681–692PubMedCrossRef

29.

Maeda T, Matsunuma A, Kurahashi I, Yanagawa T, Yoshida H, Horiuchi N (2004) Induction of osteoblast differentiation indices by statins in MC3T3-E1 cells. J Cell Biochem 92:458–471PubMedCrossRef

30.

Takenaka M, Hirade K, Tanabe K, Akamatsu S, Dohi S, Matsuno H, Kozawa O (2003) Simvastatin stimulates VEGF release via p44/p42 MAP kinase in vascular smooth muscle cells. Biochem Biophys Res Commun 301:198–203PubMedCrossRef

31.

Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866PubMedCrossRef

32.

Sharma S, Oliver-Fernandez A, Liu W, Buchholz P, Walt J (2005) The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol 16:155–159PubMedCrossRef

33.

Kowluru RA (2005) Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid Redox Signal 7:1581–1587PubMedCrossRef

34.

Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y (1999) Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274:15732–15739PubMedCrossRef

35.

Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, Glazer N, Holash J, McDonald DM, Yancopoulos GD (2000) Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 6:460–463PubMedCrossRef

36.

Krantz SB (1991) Erythropoietin. Blood 77:419–434PubMed

37.

Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N, Noguchi CT (1994) Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci U S A 91:3974–3978PubMedCrossRef

38.

Watanabe D, Suzuma K, Matsui S, Kurimoto M, Kiryu J, Kita M, Suzuma I, Ohashi H, Ojima T, Murakami T, Kobayashi T, Masuda S, Nagao M, Yoshimura N, Takagi H (2005) Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 353:782–792PubMedCrossRef

Title: Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes
Authors: Sul Gee Lee
Jung Lim Kim
Han Kee Lee
Gyu Won Ryu
Dae Young Hur
Il Han Yun
Jae Wook Yang
Hyun Woong Kim
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 3/2011
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-010-1496-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2011

IL-2 and IFN-gamma and diabetic retinopathy

Fundus fluorescein angiography and OCT

Erratum to: Anterior stromal puncture for treatment of contact lens-intolerant keratoconus patients

Response to fluorescein angiography and OCT

Second sight? Ecker JL, Dumitrescu ON, Wong KY, Alam NM, Chen SK, LeGates T, Renna JM, Prusky GT, Berson DM, Hattar S (2010) Melanopsin-expressing retinal ganglion-cell photoreceptors: cellular diversity and role in pattern vision. Neuron 67:49–60

The effect of doxycycline temperature-sensitive hydrogel on inhibiting the corneal neovascularization induced by BFGF in rats